MX2024007907A - Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo. - Google Patents
Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo.Info
- Publication number
- MX2024007907A MX2024007907A MX2024007907A MX2024007907A MX2024007907A MX 2024007907 A MX2024007907 A MX 2024007907A MX 2024007907 A MX2024007907 A MX 2024007907A MX 2024007907 A MX2024007907 A MX 2024007907A MX 2024007907 A MX2024007907 A MX 2024007907A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- preparation
- crystalline form
- method therefor
- receptor agonist
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 dioxane-5-yl Chemical group 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111586541 | 2021-12-23 | ||
| PCT/CN2022/141407 WO2023116879A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007907A true MX2024007907A (es) | 2024-07-12 |
Family
ID=86901327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007907A MX2024007907A (es) | 2021-12-23 | 2022-12-23 | Forma cristalina del agonista del receptor de peptido 1 similar al glucagon y metodo de preparacion del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049778A1 (enExample) |
| EP (2) | EP4455140B1 (enExample) |
| JP (1) | JP2024547112A (enExample) |
| KR (1) | KR20240125004A (enExample) |
| CN (1) | CN118401518A (enExample) |
| AU (1) | AU2022422997A1 (enExample) |
| CA (1) | CA3241677A1 (enExample) |
| MX (1) | MX2024007907A (enExample) |
| TW (1) | TW202328115A (enExample) |
| WO (1) | WO2023116879A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP2023528565A (ja) * | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| PL4157832T3 (pl) * | 2020-05-27 | 2024-12-16 | Qilu Regor Therapeutics Inc. | Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania |
| CN119930605A (zh) * | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022228490A1 (zh) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 JP JP2024537982A patent/JP2024547112A/ja active Pending
- 2022-12-23 US US18/722,345 patent/US20250049778A1/en active Pending
- 2022-12-23 KR KR1020247024148A patent/KR20240125004A/ko active Pending
- 2022-12-23 MX MX2024007907A patent/MX2024007907A/es unknown
- 2022-12-23 AU AU2022422997A patent/AU2022422997A1/en active Pending
- 2022-12-23 CN CN202280084770.1A patent/CN118401518A/zh active Pending
- 2022-12-23 CA CA3241677A patent/CA3241677A1/en active Pending
- 2022-12-23 WO PCT/CN2022/141407 patent/WO2023116879A1/zh not_active Ceased
- 2022-12-23 EP EP22910190.2A patent/EP4455140B1/en active Active
- 2022-12-23 EP EP26159633.2A patent/EP4725484A2/en active Pending
- 2022-12-23 TW TW111149828A patent/TW202328115A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240125004A (ko) | 2024-08-19 |
| CN118401518A (zh) | 2024-07-26 |
| EP4455140B1 (en) | 2026-04-01 |
| US20250049778A1 (en) | 2025-02-13 |
| EP4455140A1 (en) | 2024-10-30 |
| EP4725484A2 (en) | 2026-04-15 |
| EP4455140A4 (en) | 2025-04-09 |
| CA3241677A1 (en) | 2023-06-29 |
| JP2024547112A (ja) | 2024-12-26 |
| TW202328115A (zh) | 2023-07-16 |
| WO2023116879A1 (zh) | 2023-06-29 |
| AU2022422997A1 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3241677A1 (en) | Crystalline form of glp-1 receptor agonist and preparation method therefor | |
| CA3241670A1 (en) | Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor | |
| ES3066183T3 (en) | 2-(((2,3-dihydrobenzo[b][1,4]dioxan-5-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid derivatives and similar compounds as glp-1 modulators for the treatment of diabetes | |
| ZA202207589B (en) | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt | |
| MX2025011326A (es) | Formas polimorficas y sales de un agonista de glp-1r | |
| PL213103B1 (pl) | Podstawiona pochodna pirazolu, jej zastosowanie i zawierajaca ja kompozycja farmaceutyczna | |
| AU7115300A (en) | Oxazole ppar antagonists | |
| PE20010406A1 (es) | ACIDO 2-{2-METIL-4[({4-METIL-2[4-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-5-IL}METIL)SULFANIL]FENOXI}ACETICO COMO AGONISTA DEL hPPARd | |
| PE20120775A1 (es) | Derivados de tienopirimidindiona como moduladores de trpa1 | |
| DE60218703D1 (de) | (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer | |
| ATE432007T1 (de) | Fungizide ternäre wirkstoffkombinationen | |
| US20020068830A1 (en) | 1,3-dihydro-1-(phenylalkyl)-2h-imidazol-2-one derivatives | |
| DE69007740D1 (de) | Substituierte 5-[(Tetrazolyl)alkenyl]-Imidazole. | |
| CR20230162A (es) | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos | |
| MX2022016388A (es) | Compuestos de piperidina sustituida y su uso. | |
| MX2022015221A (es) | Procesos para preparar un inhibidor de cinasa jano 1 (jak1). | |
| EP1153919A4 (en) | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 ADRENERGIC RECEPTOR AGONIST USING THE SAME | |
| PE20010153A1 (es) | Derivados de 4-fenil-pirimidina como antagonistas del receptor de neuroquinina | |
| MX2025010616A (es) | Metodos para la preparacion de agonistas de sstr4 y sales de estos | |
| PE20060632A1 (es) | Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a | |
| PE20010954A1 (es) | Bencimidazoles, su preparacion y su empleo como medicamentos | |
| PE20030708A1 (es) | Derivados de piperazina desestabilizantes del receptor de androgenos | |
| MX2024010565A (es) | Procedimiento de fabricacion de un antagonista cristalino del receptor edg-2. | |
| ES2117557B1 (es) | Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina. | |
| JP2004525983A5 (enExample) |